{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:29Z","timestamp":1792242329973,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40261-023-01272-9","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:35:01Z","timestamp":1684164901000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database"],"prefix":"10.1007","volume":"43","author":[{"given":"Emily E.","family":"Leppien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett J.","family":"Doughty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyssa L.","family":"Hurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keira N.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"issue":"9","key":"1272_CR1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1080\/03007995.2020.1776234","volume":"36","author":"B Mesraoua","year":"2020","unstructured":"Mesraoua B, Deleu D, Hassan AH, et\u00a0al. Dramatic outcomes in epilepsy: depression, suicide, injuries, and mortality. Curr Med Res Opin. 2020;36(9):1473\u201380.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1272_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1535-7511.2009.01294.x","volume":"9","author":"AM Kanner","year":"2009","unstructured":"Kanner AM. Suicidality and epilepsy: a complex relationship that remains misunderstood and underestimated. Epilepsy Curr. 2009;9(3):63\u20136.","journal-title":"Epilepsy Curr."},{"key":"1272_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.yebeh.2016.05.028","volume":"61","author":"N Tian","year":"2016","unstructured":"Tian N, Cui W, Zack M, Kobau R, Fowler KA, Hesdorffer DC. Suicide among people with epilepsy: a population-based analysis of data from the US National Violent Death Reporting System, 17 states, 2003\u20132011. Epilepsy Behav. 2016;61:210\u20137.","journal-title":"Epilepsy Behav."},{"issue":"8","key":"1272_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijerph16081451","volume":"16","author":"N Abraham","year":"2019","unstructured":"Abraham N, Buvanaswari P, Rathakrishnan R, et\u00a0al. A meta-analysis of the rates of suicide ideation, attempts and deaths in people with epilepsy. Int J Environ Res Public Health. 2019;16(8):1451.","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"1272_CR5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1212\/WNL.0b013e31827b1ae0","volume":"80","author":"KM Fiest","year":"2013","unstructured":"Fiest KM, Dykeman J, Patten SB, et\u00a0al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590\u20139.","journal-title":"Neurology"},{"issue":"8","key":"1272_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(07)70175-8","volume":"6","author":"J Christensen","year":"2007","unstructured":"Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007;6(8):693\u20138.","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"1272_CR7","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.yebeh.2003.08.019","volume":"4","author":"JE Jones","year":"2003","unstructured":"Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav. 2003;4(Suppl 3):S31\u20138.","journal-title":"Epilepsy Behav"},{"key":"1272_CR8","unstructured":"US Department of Health and Human Services. Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. Accessed February 22, 2022. https:\/\/www.fda.gov\/files\/drugs\/published\/Statistical-Review-and-Evaluation--Antiepileptic-Drugs-and-Suicidality.pdf"},{"issue":"13","key":"1272_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327(13):1269\u201381.","journal-title":"JAMA"},{"issue":"2","key":"1272_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","volume":"91","author":"AM Kanner","year":"2018","unstructured":"Kanner AM, Ashman E, Gloss D, et\u00a0al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs i: treatment of new-onset epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):74\u201381.","journal-title":"Neurology"},{"issue":"9","key":"1272_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: From bromide salts to cenobamate and beyond [published correction appears. CNS Drugs. 2021;35(9):935\u201363.","journal-title":"CNS Drugs"},{"issue":"3","key":"1272_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","volume":"23","author":"FMC Besag","year":"2021","unstructured":"Besag FMC, Vasey MJ. Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy. Paediatr Drugs. 2021;23(3):253\u201386.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"1272_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/npr2.12196","volume":"41","author":"T Hakami","year":"2021","unstructured":"Hakami T. Neuropharmacology of antiseizure drugs. Neuropsychopharmacol Rep. 2021;41(3):336\u201351.","journal-title":"Neuropsychopharmacol Rep."},{"issue":"9","key":"1272_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","volume":"78","author":"P Klein","year":"2021","unstructured":"Klein P, Devinsky O, French J, et\u00a0al. Suicidality risk of newer antiseizure medications: a meta-analysis. JAMA Neurol. 2021;78(9):1118\u201327.","journal-title":"JAMA Neurol"},{"key":"1272_CR15","doi-asserted-by":"crossref","unstructured":"Brown E. Medical Dictionary for Regulatory Activities (MedDRA). Pharmacovigilance. John Wiley & Sons, Ltd, NJ; 2006;168-83","DOI":"10.1002\/9780470059210.ch13"},{"key":"1272_CR16","unstructured":"Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070093.htm. Published October 22, 2021. Accessed August 7, 2022."},{"key":"1272_CR17","unstructured":"Food and Drug Administration. National Drug Code Directory. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/national-drug-code-directory Published July 22, 2022. Accessed August 7, 2022."},{"key":"1272_CR18","unstructured":"GraphPad Prism version 9.3.0 for Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com"},{"key":"1272_CR19","unstructured":"Center for Drug Evaluation and Research. Application number: 205836Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/205836Orig1s000_205837Orig1s000_205838Orig1s000MedR.pdf Accessed September 10, 2022."},{"key":"1272_CR20","unstructured":"Center for Drug Evaluation and Research. Application number: 202834Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202834Orig1s000MedR.pdf Accessed September 10, 2022."},{"key":"1272_CR21","unstructured":"Center for Drug Evaluation and Research. Application number: 203993Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/205836Orig1s000_205837Orig1s000_205838Orig1s000MedR.pdf Accessed September 10, 2022"},{"key":"1272_CR22","unstructured":"Center for Drug Evaluation and Research. Application number: 022255Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022255Orig1s000Approv.pdf Accessed September 10, 2022."},{"key":"1272_CR23","unstructured":"Center for Drug Evaluation and Research. Application number: 22-006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022006s000_MedR.pdf Accessed September 10, 2022."},{"key":"1272_CR24","doi-asserted-by":"crossref","first-page":"2064027","DOI":"10.1155\/2018\/2064027","volume":"2018","author":"CC Hansen","year":"2018","unstructured":"Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018;2018:2064027.","journal-title":"Behav Neurol"},{"key":"1272_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2010.410","volume":"303","author":"E Patorno","year":"2010","unstructured":"Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303:1401\u20139.","journal-title":"JAMA"},{"key":"1272_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1741-7015-8-4","volume":"8","author":"AC VanCott","year":"2010","unstructured":"VanCott AC, Cramer JA, Copeland LA, Zeber JE, Steinman MA, Dersh JJ, et\u00a0al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med. 2010;8:4.","journal-title":"BMC Med"},{"issue":"2","key":"1272_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000356807","volume":"42","author":"P Ferrer","year":"2014","unstructured":"Ferrer P, Ballar\u00edn E, Sabat\u00e9 M, et\u00a0al. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology. 2014;42(2):107\u201320.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"1272_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamapsychiatry.2015.2516","volume":"73","author":"DC Hesdorffer","year":"2016","unstructured":"Hesdorffer DC, Ishihara L, Webb DJ, Mynepalli L, Galwey NW, Hauser WA. Occurrence and recurrence of attempted suicide among people with epilepsy. JAMA Psychiat. 2016;73(1):80\u20136.","journal-title":"JAMA Psychiat"},{"key":"1272_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.yebeh.2018.06.024","volume":"87","author":"D Friedman","year":"2018","unstructured":"Friedman D, Spruill TM, Liu H, et\u00a0al. Depressive symptoms and suicidality among individuals with epilepsy enrolled in self-management studies: results from the US centers for disease control and prevention Managing Epilepsy Well (MEW) network. Epilepsy Behav. 2018;87:235\u201340.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"1272_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.25623","volume":"86","author":"JW Dreier","year":"2019","unstructured":"Dreier JW, Pedersen CB, Gasse C, Christensen J. Antiepileptic drugs and suicide: Role of prior suicidal behavior and parental psychiatric disorder. Ann Neurol. 2019;86(6):951\u201361.","journal-title":"Ann Neurol"},{"issue":"1","key":"1272_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/15357597211053193","volume":"22","author":"E Faught","year":"2022","unstructured":"Faught E. Suicidality: once again, don\u2019t blame the drug class. Epilepsy Curr. 2022;22(1):28\u201330.","journal-title":"Epilepsy Curr"},{"issue":"1","key":"1272_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1528-1167.2012.03688.x","volume":"54","author":"M Mula","year":"2013","unstructured":"Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54(1):199\u2013203.","journal-title":"Epilepsia"},{"issue":"11","key":"1272_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40264-016-0455-4","volume":"39","author":"S Stergiopoulos","year":"2016","unstructured":"Stergiopoulos S, Brown CA, Felix T, Grampp G, Getz KA. A survey of adverse event reporting practices among US healthcare professionals. Drug Saf. 2016;39(11):1117\u201327.","journal-title":"Drug Saf"},{"issue":"4","key":"1272_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01272-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:52:14Z","timestamp":1702425134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01272-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"17 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Brian J Piper was (2019\u201321) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. Dr. Piper is part of a\u00a0medical marijuana research team\u00a0supported\u00a0by the Geisinger Academic Clinical Research Center.\u00a0Dr. Bennett Doughty is a paid speaker of Otsuka\u2019s PsychU platform. The other authors have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was approved by the Binghamton University Institutional Review Board. IRB ID# STUDY00003621 June 7, 2022.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"A publicly available dataset was analyzed in this study. This data can be found here:.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors were involved in the study conceptualization, development of methodology, and analysis. All authors were involved in writing, reviewing, and editing the manuscript. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}